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We performed a MEDLINE and EMBASE search to identify all studies published in the last decade in the English
language literature on the use of progestogens for the treatment of endometriosis. Our aim was to clarify the
biological rationale for treatment and de®ne the drugs that can be used with their doses, routes of administration,
ef®cacy and tolerability. Progestogens may prevent implantation and growth of regurgitated endometrium inhibit-
ing expression of matrix metalloproteinases and angiogenesis, and they have several anti-in¯ammatory in-vitro and
in-vivo effects that may reduce the in¯ammatory state generated by the metabolic activity of the ectopic endo-
metrium, and the consequent immune response. Oral contraceptives increase the abnormally low apoptotic activity
of the endometrium of women with endometriosis. Moreover, anovulation, decidualization, amenorrhoea and the
establishment of a steady estrogen±progestogen milieu contribute to disease quiescence. Progestogens are effective
in the control of pain symptoms in approximately three out of four women with endometriosis. Their effect does not
seem to be inferior to that of other drugs used for the disease. Different compounds can be administered by the oral,
intramuscular, subcutaneous, intravaginal or intrauterine route, each with speci®c advantages or disadvantages.
Medical treatment plays a role in the therapeutic strategy when administered over a prolonged period of time.
Given their good tolerability, minor metabolic effects and low cost, progestogens must therefore be considered
drugs of choice and are currently the only safe and economic alternative to surgery. However, their contraceptive
effectiveness limits their use to women who do not wish to have children in the short term.
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Introduction
Drugs used in the treatment of endometriosis are not cytoreductive
(Prentice, 2001), which belies the common conviction that, if a
treatment determines a suf®ciently deep hypo-estrogenism and is
administered for an adequate period of time, it may induce necrosis,
resorption and disappearance of ectopic endometrial foci. However,
this cannot be true as quiescent implants have been demonstrated in
nearly all women treated with danazol, GnRH agonists and
progestogens (Nisolle-Pochet et al., 1988). At restoration of
ovulation and of physiological levels of estrogens, the endo-
metrium, both eutopic and ectopic, resumes its metabolic activity.
As a consequence, medical therapy is symptomatic and pain relapse
at treatment suspension is the rule (Vercellini et al., 1997a).
Drugs that are administered for relatively few months only, due
to their poor tolerability, severe metabolic side-effects or high
cost, do not greatly bene®t women with symptomatic endome-
triosis. Progestogens alone or combined with estrogens are instead
generally well-tolerated, have a more limited metabolic impact
than danazol or GnRH agonists, are inexpensive and may be used
on a long-term basis (Vercellini et al., 1997a; Moore et al., 2003;
Prentice et al., 2003).
After more than 20 years on the sidelines, progestogens are
gradually regaining popularity as a treatment for endometriosis.
Hence we considered it interesting to perform a review of the most
recent biological and clinical studies on the topic published in the
last decade. Reports that appeared before 1993, generally deemed
of suboptimal quality, are considered in a previous overview
(Vercellini et al., 1997a). A qualitative and quantitative analysis of
comparative trials with pooling of results is not among the aims of
the present narrative review, and reference is suggested to the
Cochrane Collaboration meta-analyses (Moore et al., 2003;
Prentice et al., 2003).
Materials and methods
Several different strategies were adopted to identify all English
language medical papers published on progestogen treatment for
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endometriosis. We conducted a MEDLINE and an EMBASE search
from January 1993 to March 2003 using combinations of medical
subject heading terms: endometriosis, pelvic pain, dysmenorrhoea,
dyspareunia, progestogens, oral contraceptives, and medical therapy.
All pertinent articles were retrieved and additional reports were then
identi®ed by systematically reviewing all references. In addition,
books and monographs on endometriosis published in the last 10 years
were consulted. Proceedings of scienti®c meetings were also included.
Two authors (G.P. and G.F.) abstracted data on standardized forms.
An initial screening of the title and abstract of all articles was
performed to exclude citations deemed irrelevant by both observers.
The year of publication, type and design of the study, experimental
setting, clinical characteristics of subjects, and treatment schedule
were recorded.
In the biological section, only studies on novel anti-in¯ammatory or
immunomodulatory effects were considered, excluding those focusing
on the already well-known properties of progestogens in terms of
progesterone receptor-inducing and anti-mitotic activities, as well as
induction of secretory changes and decidualization. The search was
limited to progestogens currently used in the treatment of
endometriosis. In the clinical section, only the effect on pain were
considered, as it has been repeatedly and de®nitively demonstrated
that there is no bene®cial effect of any medical therapy on
endometriosis-associated infertility (Candiani et al., 1990; Hughes
et al., 1993; Olive and Pritts, 2001).
Results
Biological rationale for the use of progestogens in the treatment
of endometriosis (Table I)
Progestogens may inhibit the implantation and growth of
regurgitated endometrium via various biological mechanisms.
During the menstrual cycle in response to serum level
variations of ovarian steroids, the endometrium produces
various bioactive growth factors and cytokines, which are
essential elements of paracrine communication. The latter
determines the expression of matrix metalloproteinases
(MMP), enzymes which mediate tissue remodelling during
the menstrual cycle. Endometriotic disease arises as a conse-
quence of retrograde menstruation, and MMP seem to
contribute to the implantation and growth of ectopic endome-
trium in the peritoneal cavity. Although the risk of developing
endometriosis is generically associated with exposure to
ovarian steroids, paracrine factors produced locally may
modify steroidal action on multiple genetic targets, including
MMP (Osteen et al., 2002). Growth factors associated with
estrogens and in¯ammatory cytokines stimulate intensely the
expression of MMP and can add to the capacity of endometrial
fragments for invading the peritoneal surface and establishing
ectopic implants. Contrarily, paracrine factors associated with
the effect of progesterone during initial pregnancy inhibit
expression of MMP and, in an experimental model, prevent
growth of ectopic endometrium (Osteen et al., 2002).
Once implanted, ectopic endometrium produces angioge-
netic factors to induce the formation of new capillaries from
existing vessels. In the adult, angiogenesis is limited to few
tissues, including uterus and ovaries, but occurs commonly
during tumour growth and in other diseases such as
endometriosis. The ®rst step of angiogenesis involves local
degradation of the basement membrane and extracellular
matrix by proteolytic enzymes such as plasminogen activator
and MMP as described above (Hyder and Stancel, 1999). An
anti-angiogenetic action of medroxyprogesterone acetate
(MPA) has been repeatedly demonstrated. In fact, MPA
suppresses plasminogen activator activity by means of stimu-
lation of plasminogen activator inhibitor synthesis (Blei et al.,
1993; Schatz and Lockwood, 1993) (Table I).
Dienogest is a synthetic steroid used as a progestogen in oral
contraceptive (OC) pills and its possible clinical application in
the treatment of endometriosis is currently being studied. In an
experimental model, it has been demonstrated that dienogest
also inhibits angiogenesis (Nakamura et al., 1999), reduces the
volume of autologous transplanted endometrium in rats,
increases the natural killer activity of peritoneal ¯uid cells,
decreases the number of in¯ammatory peritoneal ¯uid cells,
and decreases interleukin-1b production by peritoneal macro-
Table I. Experimental biological effects of progestogens used for the treatment of endometriosis: literature data, 1993±2003
Drug Biological effects Source
Medroxyprogesterone acetate Inhibition of angiogenesis via stimulation of plasminogen activator inhibitor synthesis in vitro Blei et al. (1993)
Progesterone receptor-mediated down-regulation of endometrial RANTES gene transcription in vitro Zhao et al. (2002)
Inhibition of nuclear factor K-B transcription activity in vitro
Dienogest Normalization of peritoneal ¯uid cell number in vivo Katsuki et al. (1998)
Decrease in peritoneal macrophages interleukin-1b production in vivo
Increase in peritoneal ¯uid cells natural killer activity in vivo
Inhibition of rat endometrial cell protein kinase C activity in vitro
Inhibition of angiogenesis in vivo Nakamura et al. (1999)
Induction of prolactin production by human endometrial stromal cells in vitro Okada et al. (2001)
Inhibition of proliferation of human endometrial stromal cells in vitro
Oral contraceptivea Decreased expression of Ki-67 protein in the eutopic endometrium of women with endometriosis Meresman et al. (2002)
Increased endometrial apoptosis in women with endometriosis
Decreased expression of Bcl-2 and increased expression of Bax in the eutopic endometrium
of women with endometriosis
aDesogestrel 0.15 mg + ethinyl estradiol 0.03 mg.
RANTES = regulated on activation, normal T-cell expressed and secreted; Bcl-2 = B cell lymphoma/leukaemia-2.
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phages (Katsuki et al., 1998). Furthermore, Okada et al. (2001)
analysed the direct effects of dienogest in the differentiation
and proliferation of in-vitro human endometrial stromal cells.
After 12 days in the presence of ústradiol and dienogest, the
endometrial stromal cells have shown morphological differen-
tiation and started to produce prolactin, a typical marker of
decidualization. Prolactin production induced by dienogest is
dose-dependent and is almost completely inhibited by the
addition of RU 486, a progesterone antagonist. Furthermore, as
demonstrated by the uptake of thymidine, dienogest causes a
dose-dependent inhibition of stromal endometrial cell prolif-
eration. This inhibitory effect is partially abolished by RU 486.
Once the regurgitated endometrium has disrupted the
peritoneal basal membrane, reached the submesothelial
collagen matrix, and induced angiogenesis, it resumes its
metabolic activity, generating an in¯ammatory condition. An
in¯ammatory pelvic exudate is a common ®nding in women
with endometriosis and is expressed as an increase in the
volume of peritoneal ¯uid as well as in number of leukocytes,
and an elevated concentration of proteases. Haney and
Weinberg (1988) were the ®rst to prove the anti-in¯ammatory
action of progestogen therapy. In 16 infertile women with
endometriosis, administration of 30 mg/day of MPA for 4
months signi®cantly reduced the volume of the peritoneal ¯uid,
the number of leukocytes and the revised American Fertility
Society (R-AFS) classi®cation (American Fertility Society,
1985).
The anti-in¯ammatory properties of MPA in women with
endometriosis may be due to reduction of chemokine synthesis.
RANTES (regulated on activation, normal T-cell expressed
and secreted) is a chemokine synthesized by stromal eutopic
and ectopic endometrial cells, circulates in the peritoneal ¯uid,
and acts as a chemoattractant for monocytes and activated T
cells, the two predominant leukocytes in peritoneal ¯uid of
women with endometriosis (Zhao et al., 2002). Indeed,
RANTES concentration and bioactivity are elevated in
peritoneal ¯uid of patients with the disease. The prolonged
administration (8 days) of MPA to cultures of endometrial
stromal cells causes a reduction of 36% in luciferase activity
and of 50% in RANTES protein synthesis, whereas a briefer
treatment (2 or 4 days) does not produce signi®cant effects. The
administration of MPA for 8 days increases expression of
progesterone receptor (PR). Both effects are blocked by RU
486. A prolonged progestogen exposure induces a down-
regulation of gene transcription of in-vitro endometrial
RANTES. Such an effect is PR-dependent and is partially
mediated by a nuclear factor (Zhao et al., 2002). According to
Zhao et al. (2002), the ef®cacy of progestogen therapy in
endometriosis-associated pelvic pain could therefore be due to
inhibition of RANTES production and suppression of the
pelvic in¯ammatory response.
The effect of OC on regulation of in-vitro endometrial cell
growth has recently been studied by Meresman et al. (2002) in
biopsy specimens obtained from 13 women with endometriosis
and 13 controls. Apoptosis (or programmed cell death) of the
endometrium is regulated by steroid hormones and is
controlled by the expression of several regulatory genes. The
proto-oncogene B cell lymphoma/leukaemia-2 (Bcl-2) blocks
apoptosis, whereas the Bax protein antagonizes its survival
activity. The Bcl-2/Bax ratio predetermines susceptibility of
cells to apoptotic inducers. Eutopic epithelial and stromal
endometrial cells from patients with endometriosis show an
augmented survival capability probably caused by an abnor-
mally high effect of Bcl-2. Exposure to a monophasic OC for
30 days signi®cantly increases endometrial apoptosis in
comparison with pre-treatment levels, both in epithelial and
stromal cells, producing values similar to those observed in the
endometrium from women controls without endometriosis
(Meresman et al., 2002). In fact, OC administration reverses
the abnormal increment in Bcl-2 expression in patients with
endometriosis, and induces a major increase in the Bax protein
expression. Furthermore, endometrial cell proliferation in
subjects with the disease is signi®cantly reduced by exposure
to an OC.
The anti-angiogenetic, anti-in¯ammatory and immunomo-
dulatory effects, down-regulation of endometrial cell prolifer-
ation and increase in apoptotic activity, all constitute a
convincing rational basis for the use of progestogens, alone
or combined with estrogens, in the treatment of endometriosis.
Clinical effect of progestogens and estrogen±progestogens in
women with symptomatic endometriosis (Table II)
Oral route
Medroxyprogesterone acetate. MPA is a 17-hydroxy derivate
progestogen with moderate androgenic activity and minor
effects on the lipoproteic asset. Its oral use in the treatment of
symptomatic endometriosis has recently been evaluated in two
randomized controlled trials.
Harrison and Barry-Kinsella (2000) allocated 100 infertile
women with endometriosis to treatment with MPA 50 mg/day
for 3 months or placebo. No difference between groups was
detected in score variations of the R-AFS classi®cation
(American Fertility Society, 1985) at repeat laparoscopy at
the end of therapy. Six pregnancies occurred in the placebo
group and one in the MPA group. However, pain symptoms
were reduced more signi®cantly in the latter group than in the
former. In addition, 85% of symptomatic women allocated to
MPA deemed such therapy effective in improving overall well-
being, versus 41% in those allocated to placebo. Both groups
reported minimal side-effects (in 10% of the MPA-treated
patients and 2% of the ones given placebo).
In a double-blind, double-dummy study, Bergqvist and
Theorell (2001) compared a 6 month treatment with nasal
nafarelin, 400 mg/day versus oral MPA, 15 mg/day. Of the 48
women initially recruited, 18 dropped out (six in the nafarelin
group, 12 in the MPA group) principally due to anxiety±
depressive disturbances. The results showed a considerable
reduction in pain symptoms scores with no signi®cant differ-
ences between study groups. The anxiety depression score
worsened during use of nafarelin. All other psycho-social
parameters as well as overall emotional balance improved
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during the study period with no signi®cant differences between
groups.
Evidence that MPA is more ef®cacious than placebo but no
less ef®cacious than GnRH agonists in reducing pain and in
improving health-related quality of life, suggests its use in
women with symptomatic endometriosis. However, erratic
bleeding episodes may be more frequent and prolonged with
MPA compared with other progestogens. Furthermore, the
optimal dosage of the drug still needs to be determined.
Cyproterone acetate (CPA). This derivative of 17-hydro-
xyprogesterone, with anti-androgenic and anti-gonadotrophic
properties, was ®rst used in the treatment of endometriosis by
Fedele et al. (1989) at the dosage of 27 mg/day.
Subsequently Moran et al. (1996) evaluated the ef®cacy of a
6 month treatment with CPA at a reduced dosage (10 mg/day
for 20 days followed by 10 days with no treatment) in seven
women affected by mild-to-severe symptomatic endometriosis.
Dysmenorrhoea was considerably relieved in all the subjects,
with oligomenorrhoea reported by six and spotting by one. A
repeat laparoscopy at the end of treatment demonstrated
minimal residual lesions in ®ve women and absence of disease
in two.
A similar dosage (12.5 mg/day) but administered continu-
ously was recently tested by Vercellini et al. (2002) in a
randomized study that compared its effects to those of an OC,
(desogestrel 0.15 mg and ethinyl estradiol 0.02 mg) given
continuously for 6 months. Ninety women were recruited with
moderate-to-severe pelvic pain that recurred after conservative
surgery for symptomatic endometriosis. The main outcome of
the study was patients' degree of satisfaction, which was
deemed important in order to be able to consider their point of
view in the evaluation of drug ef®cacy, as well as the impact of
side-effects. Six women in the CPA arm and nine in the OC
arm dropped out due to side-effects (n = 9), treatment
inef®cacy (n = 4), or loss to follow-up (n = 2). At 6 months,
dysmenorrhoea, deep dyspareunia and non-menstrual pelvic
pain were considerably reduced. In addition the health-related
quality of life, psychological pro®le and sexual satisfaction
improved signi®cantly, with no major differences between
groups. Metabolic and subjective side-effects were limited.
According to an intention-to-treat analysis, 33/45 (73%)
women in the CPA group and 30/45 (67%) in the OC group
were satis®ed with the treatment received. Both schemes used
have therefore been shown to be an effective, safe and
inexpensive treatment for pain recurring after conservative
surgery for endometriosis. CPA may be used when subjective
and metabolic effects of estrogens need to be avoided, or in
women unwilling to use contraception because of cultural or
religious objections. On the other hand, the continuous use of a
low dose monophasic OC is most probably the preferred option
to prevent the effects of estrogen deprivation in women for
whom a long period of therapy is expected.
Dydrogesterone. Overton et al. (1994) studied dihydroges-
terone administered according to an atypical modality for the
treatment of symptomatic endometriosis. They considered that
continuous administration of progestogens inhibits ovulation,
thus excluding therapy for all women wanting children. A
triple-arm randomized study was designed, which considered
43 women wanting children allocated to dihydrogesterone 40
mg/day or 60 mg/day or to placebo administered for 12 days/
cycle in the post-ovulatory phase for 6 months. Combining the
results obtained with both doses of progestogen, dihydroges-
terone did not prove more effective than placebo in reducing
pain symptoms during treatment [odds ratio (OR) 0.8; 95%
con®dence interval (CI), 0.2±3.3] or at the end of the 12 month
follow-up (OR 1.2; 95% CI, 0.2±5.6). Such results con®rm that
continuous oral progestogen therapy, by suppressing ovulation
and creating a stable hormonal milieu, is essential in order to
achieve a satisfactory analgesic response.
Dienogest. Dienogest is the ®rst of the so-called hybrid
progestogens that, based on their unique chemical structure,
combine pharmacodynamic properties typical of progesterone
derivatives (i.e. excellent tolerability, anti-androgenic action,
diminished anti-gonadotrophic effect, a primarily peripheral
modality of action, dosage in the range of milligrams) with
those of modern 19-norprogestins that have a 17a-ethinylic
group (strong progestogen action on the endometrium, short
half-life, high bioavailability after oral administration, low
hepatic, toxicological and genotoxicological impact, and
adequate control of uterine bleeding if combined with
ústrogens) (Foster and Wilde, 1998; Oettel et al., 1999;
Zimmermann et al., 1999). Dienogest does not accumulate in
serum although high serum concentrations are obtained after
oral administration of only 2 mg, and does not reduce sex
hormone-binding globulin (SHBG) serum levels (Kuhl, 1996).
Data on the ef®cacy of dienogest in the treatment of
symptomatic endometriosis are scanty. Moore et al. (1999)
collected the results of three clinical studies conducted on a
total of 267 patients with symptomatic endometriosis A 6
month treatment with dienogest at the oral dose of 2±4 mg/day
was shown to be as effective as danazol, GnRH agonists and
other progestogens in terms of improving dysmenorrhoea and
pelvic pain, as well as regression or disappearance of
endometriotic implants. According to the authors, the advan-
tage of dienogest lies in its safe pro®le, which includes good
tolerability and fewer side-effects compared with most treat-
ments commonly used.
Dienogest seems to constitute a promising alternative in the
therapeutic horizon for patients with endometriosis.
Nonetheless, in order to draw ®nal conclusions there is a
need for more robust data originating from adequately
designed clinical studies.
Lynestrenol. Effects of a 6 month treatment with the
progestogen lynestrenol (10 mg/day post-operatively) were
compared with those of the GnRH leuprolide depot formula-
tion (3.75 mg monthly s.c. injections) in a randomized study
conducted on 48 women who had undergone operative
laparoscopy for endometriosis (Regidor et al., 2001). The
GnRH agonist produced a more pronounced regression of
lesions and of R-AFS scores (American Fertility Society, 1985)
at a repeat laparoscopy, a deeper hypo-estrogenism (mean
serum 17b-oestradiol levels, 28 6 9 versus 43 6 59 pg/ml), as
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well as a greater reduction of dysmenorrhoea, dyspareunia and
chronic pelvic pain compared with the progestogen. Because
treatment with leuprolide cannot be prolonged for more than a
few months, the authors suggest the use of lynestrenol as a
second-line drug to maintain the bene®cial effects obtained
with the GnRH agonist.
Norethisterone acetate. Norethisterone acetate (or norethin-
drone acetate, NETA) is a strong progestogen derivative of 19-
nortestosterone. Its ef®cacy was studied by Muneyyirci-Delale
and Karacan (1998) in 52 women with symptomatic and
laparoscopically con®rmed endometriosis. NETA was started
at the beginning of the menstrual cycle at a daily dose of 5 mg,
which was increased by 2.5 mg up to 20 mg/day until
amenorrhoea was achieved. Treatment was continued for 6
months to >1 year. Dysmenorrhoea regressed in 48/52 (92%)
subjects and chronic pelvic pain in 25/28 (89%). At the end of
treatment, 49/52 (94%) women had few or no symptoms.
Breakthrough bleeding was experienced by 30 (58%) patients,
causing four (8%) to drop out. One other patient suspended
therapy for severe breast tenderness, and three patients for
inef®cacy. Overall, treatment was successful in 44/52 (84%)
recruited subjects.
Moore et al. (1999) compared the effect of a 6 month oral
treatment with dienogest 2 mg/day (n = 119) versus NETA 10
mg/day (n = 48). Pain relief at the end of therapy was similar,
being obtained in 88/97 (91%) of the former group and 46/48
(96%) of the latter.
NETA offers various advantages for the long-term treatment
of endometriosis. This progestogen allows good control of
uterine bleeding as compared with other compounds, has a
positive effect on calcium metabolism by producing greater
increases in bone mineral density than alendronate, and at low
dosages has no negative effects on the lipoprotein pro®le (Riis
et al., 2002).
NETA administered continuously to treat endometriosis is
approved by the United States Food and Drug Administration
and the Italian Ministry of Health.
Tibolone. Tibolone is a synthetic steroid with weak
estrogenic, progestinic and androgenic activity. The effect of
tibolone on the endometrium is inhibitory, as the progestinic±
androgenic activity is prevalent. In vitro, tibolone is metabo-
lized by endometrial D4 isomerase/dehydrogenase to its D4
metabolite, which is characterized by strong progestinic
activity. This explains its endometrial tissue-speci®c proges-
tinic effect as well as a positive effect on calcium metabolism.
Fedele et al. (1999) compared the effects of treatment with
transdermal estradiol (50 mg twice weekly 6 cyclic MPA 10
mg/day) to those of tibolone (2.5 mg/day p.o.), given for a
minimum of 12 months to 21 women with residual pelvic
endometriosis after bilateral oophorectomy with or without
hysterectomy. Residual endometriosis was found in the bowel
wall in four subjects, in the rectovaginal septum in six and deep
in the retroperitoneal pelvic space in six. All women were
symptomatic before de®nitive surgery. Moderate-to-severe
pain recurred in four subjects in the transdermal estradiol arm
versus one in the tibolone arm. These results suggest that
tibolone may be considered the drug of choice as post-
menopausal replacement treatment for women with pelvic
endometriosis. In addition, tibolone may constitute an optimal
choice as add-back therapy in selected candidates for pro-
longed treatment with GnRH agonists (Lindsay et al., 1996).
Intramuscular route. The depot formulation of MPA
(DMPA) has been widely evaluated for contraceptive purposes
and is currently being used by ~12 million women worldwide
(Kaunitz, 1994). The administration modality is extremely
convenient and consists of a single 150 mg intramuscular
injection every 3 months. The increase in risk of breast cancer
in users of DMPA is not superior to that of OC (Skegg et al.,
1995). Literature data do not suggest that depressive symptoms
may develop or worsen during use of DMPA (Westhoff et al.,
1995) whereas there is con¯icting evidence regarding the
development of bone demineralization secondary to hypo-
estrogenism in chronic users.
Results from the ®rst formal study on the use of DMPA in
patients with endometriosis were published by Vercellini et al.
(1996). The progestogen was compared with an association of a
monophasic oral contraceptive with low dose danazol (50 mg/
day). After a 1 year treatment, 29/40 women (72%) allocated to
DMPA were satis®ed versus 23/40 (57%) of those randomized
to receive the OC plus danazol. A signi®cant reduction in pain
symptoms evaluated with a visual analogue and multidimen-
sional scale has been observed in both groups. However,
patients in the combined OC/danazol group complained of a
greater frequency and severity of dysmenorrhoea, which is a
logical consequence of cyclic administration. Both treatments
induced a similar, signi®cant reduction in serum high density
lipoprotein (HDL) cholesterol levels, whereas an increase in
low density lipoprotein (LDL) cholesterol levels was only
observed in subjects allocated to the OC plus danazol
treatment. The incidence of side-effects was greater in
DMPA users. In these, the mean delay in appearance of a
regular menstrual cycle after suspension was 7 months to a
maximum of 1 year.
The ef®cacy of DMPA as a therapy for endometriosis was
recently con®rmed in a non-controlled study on 19 patients
with severe symptomatic disease (Arowojolu, 2000). In
addition to the substantial reduction in pain symptoms,
DMPA induced a signi®cant regression of ectopic foci at
follow-up laparoscopy, with complete resolution of visible
implants in 66% of study subjects.
DMPA is an effective, safe, and extremely economic
alternative for the treatment of symptomatic endometriosis.
However, because of some of its characteristics, candidates for
treatment need to be selected carefully. In fact, prolonged delay
in resumption of ovulation is a contraindication to use of
DMPA in women wanting children in the near future.
Additionally, uterine breakthrough bleeding may be prolonged,
repeated and troublesome to correct. Furthermore, treatment
cannot be interrupted in the event of side-effects, rendering
clinical management complicated when these are severe or
scarcely tolerable. Its indication of choice is residual symp-
tomatic endometriosis following de®nitive surgery. In such
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circumstances, there are no problems regarding conception or
irregular uterine bleeding, and use of DMPA allows a simple
and well-tolerated suppression of persistent foci after non-
radical operations with no need to opt for daily administration
of drugs or further surgery.
Subdermal route
Nestoroneâ is a synthetic progestogen proposed for contra-
ception. It is used parenterally as it is almost inactive after oral
administration. It is devoid of androgenic side-effects and it
inhibits ovulation when delivered by transdermal implants or
vaginal ring. Large doses of Nestorone suppress ovulation and
determine hypo-oestrogenism. YlaÈnen et al. (2003) allocated
21 patients with symptomatic endometriosis after conservative
surgery to treatment with Nestorone subdermal implants for 7
months at the dose of 150 mg/day (n = 7), 200 mg/day (n = 7), or
400 mg/day (n = 7). The implants were removed due to
persistent bleeding and pain in one case only. Two other
subjects requested removal for non-medical reasons.
Amenorrhoea was achieved in only four of the women, and
spotting was the rule in the others. Relief of menstrual pain was
reported by 81% of the patients, without signi®cant differences
in pain score reductions between the three study groups. Most
of the women experienced side-effects (insomnia, depression,
mood changes, in 57%; hot ¯ushes, sweating, vaginal dryness,
in 45%; acne in 38%; headache in 29%). Improved general
well-being was reported by 48% of the subjects, no change by
29%, and deterioration by 24%. No signi®cant changes were
observed in total, HDL and LDL cholesterol serum concentra-
tion. One month after treatment withdrawal, pain scores
approached the baseline values.
Although Nestorone has a bene®cial effect on pain
associated with endometriosis, the need for insertion of
multiple subdermal implants (and hence subsequent removal),
together with the high incidence of side-effects during
treatment, may limit its popularity as a long-term treatment
for endometriosis.
Intrauterine route
Dysmenorrhoea is by far the most frequent symptom reported
by patients with endometriosis. Menstrual pain is obviously
abolished during amenorrhoea secondary to medical treatments
that induce anovulation and hypo-estrogenism. However, when
side-effects or poor tolerability require interruption of oral or
parenteral drug therapies, pain symptoms frequently recur.
Consequently, the identi®cation of safe and effective alterna-
tives to prolong treatment constitutes an essential element in
the current clinical research on symptomatic endometriosis. In
this regard, the possibility of aiming the therapeutic action of
drugs at speci®c organs, thus reducing the general metabolic
impact, is a subject of great interest. An intrauterine device
(IUD) releasing 20 mg/day of levonorgestrel, a potent
progestogen derived from 19-nortestosterone, may induce
amenorrhoea in different ways compared with standard
treatments and may relieve menstrual pain. In fact, the local
administration of levonorgestrel has a profound effect on the
endometrium, which becomes atrophic and inactive, although
ovulation is generally not suppressed.
Vercellini et al. (1999) inserted a levonorgestrel IUD in 20
parous women who had recurrent moderate or severe
dysmenorrhoea after conservative surgery for endometriosis
and did not want more children. One IUD was expelled and one
was removed because of intolerable side-effects. One woman
was lost to follow-up. The menstrual pattern in the remaining
17 subjects was characterized by amenorrhoea in four cases,
hypomenorrhoea or spotting in eight, and normal ¯ow in ®ve.
Blood loss was measured with a semiquantitative method and
was decreased during the 12 months of study, as was
dysmenorrhoea which was evaluated according to visual
analogue and verbal multidimensional scales. Four women
were very satis®ed with treatment, 11 were satis®ed, two were
uncertain, and three were dissatis®ed.
A levonorgestrel IUD was recently used also in the treatment
of persistent rectovaginal endometriosis in 11 patients under-
going non-radical conservative surgery (Fedele et al., 2001).
One year after insertion, dysmenorrhoea, which had been
moderate or severe in all cases, and non-menstrual pelvic pain
were absent. Of notable interest was the reduction of deep
dyspareunia, from moderate or severe in eight cases prior to
IUD insertion, to absent or mild in all subjects throughout
treatment. Rectal tenesmus was also substantially alleviated.
Furthermore transrectal ultrasound scans demonstrated a
progressive reduction in size of rectovaginal lesions. The
results of this study are clinically important because they prove
the ef®cacy of a progestogen in a type of lesion generally
considered as non-responsive to medical therapy. Relief of
deep dyspareunia and rectal tenesmus seems to be due not only
to size reduction of the ®bronodular rectovaginal plaques, but
also to decrease of the intra- and perilesional in¯ammatory
condition, and con®rms the effect of treatment also on organic
symptoms.
Intrauterine administration of levonorgestrel with a possible
direct distribution to pelvic tissues would imply a local
concentration greater than its plasma levels. This could
translate into a superior effectiveness with limited side-effects,
also due to the absence of the hepatic ®rst pass following oral
administration of the drug. However, the results of the studies
conducted by Vercellini et al. (1999) and Fedele et al. (2001)
show that these expectations were partially incorrect. The side-
effects observed are typically associated with the intake of
levonorgestrel (weight gain, acne, seborrhoea, breast tender-
ness, abdominal bloating) and suggest a systemic action
deriving from uterine absorption of the drug. This seems
logical in relation to the ¯orid endo-myometrial vasculariza-
tion.
The `pill': beyond simple contraception
For many years OC have been extensively used in clinical
practice for the reduction of pelvic pain and dysmenorrhoea
associated with endometriosis. Although their effectiveness
has been recognized by all gynaecologists, only a limited
number of formal studies have quanti®ed their effects or
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compared these with those obtained during administration of
other drugs.
In the 1990s, GnRH agonists were considered the thera-
peutic reference standard for medical treatment of endome-
triosis. To test this notion, we compared the ef®cacy of a 6
month treatment with a monophasic OC (desogestrel 0.15 mg
and ethinyl estradiol 0.02 mg, 28 patients) administered
cyclically versus goserelin depot (3.6 mg s.c. every 28 days,
29 patients) (Vercellini et al., 1993). At the end of treatment, a
signi®cant reduction in deep dyspareunia was observed in both
groups, with goserelin assessed as superior to the OC. Non-
menstrual pain was diminished without differences between
treatments. Women taking the OC experienced a signi®cant
reduction in dysmenorrhoea. With respect to the latter symp-
tom, a comparison with GnRH is impracticable due to
amenorrhoea secondary to hypo-estrogenism. Symptoms
recurred unaltered 6 months after drug withdrawal.
Parazzini et al. (2000) investigated whether a GnRH agonist
(triptorelin 3.75 mg i.m. every 28 days, 47 patients) admin-
istered for 4 months before starting treatment with a cyclic OC
would improve results compared with the immediate use of an
estrogen±progestogen combination (gestodene 0.75 mg and
ethinyl estradiol 0.03 mg, 55 patients) for 12 months. One year
after randomization, the two treatment modalities showed
similar relief of pelvic pain in women with endometriosis. No
data are available to support the belief that estrogen-
progestogen combinations are to be considered as second-
line drugs. When a long-term use is indicated, an OC may be
prescribed without need of `preparation' with a GnRH agonist.
OC used cyclically are the only treatment for endometriosis
that permits monthly uterine bleeding. Dysmenorrhoea is
known as the most frequent and most severe complaint in
women with this disease. The symptom may therefore not
subside completely during administration of an OC. Recent
studies have demonstrated that women with menstrual-related
problems during cyclic use of an OC may bene®t from a shift to
continuous administration (Sulak et al., 1997; 2002). Although
elimination of the 7 day interval is recommended by various
experts, there are no speci®c data regarding women with
endometriosis. Consequently, we prescribed a monophasic OC
(desogestrel 0.15 mg and ethinyl estradiol 0.02 mg) continu-
ously to 50 patients with dysmenorrhoea recurring after
conservative surgery for endometriosis, and not responding
to the cyclic use of the same OC (Vercellini et al., 2003b).
During the 2 year study period, 38% of women reported
amenorrhoea, 36% spotting and 26% breakthrough bleeding.
The mean score of menstrual pain, evaluated according to a
100-mm visual analogue scale, showed a reduction from 75 6
13 to 31 6 17. Moderate or severe side-effects were reported
by 14% of the women. At ®nal evaluation 26% of subjects were
very satis®ed, 54% satis®ed, 2% uncertain, 16% unsatis®ed
and 2% very unsatis®ed.
When cyclic use of OC does not resolve pain associated with
monthly bleeding, continuous administration might constitute a
simple, effective, safe and well-tolerated option for long-term
treatment in women not wanting children.
Progestogens as post-operative adjuvant treatment
In spite of the lack of evidence demonstrating necrosis and
disappearance of residual foci following medical treatments
after surgery for endometriosis, the urge to prescribe such
treatments seems to be overzealous. These schemes, which
have clearly been derived from oncological practice, have a
clinical signi®cance only if prolonged over an extended period
of time in women not wanting children immediately. Again,
progestogens and estrogen±progestogen combinations consti-
tute the only reasonable alternative for endometrial suppression
of longer duration with respect to the conventional, arbitrary 6-
month period.
In a randomised controlled study, Muzii et al. (2000)
demonstrated that administration of a low dose monophasic
estrogen±progestogen combination after operative laparoscopy
for symptomatic endometriosis signi®cantly reduces the
cumulative probability of pain recurrence and increases the
symptom-free period, compared to postsurgical expectant
management.
Results of a randomized, controlled multicentre European
trial on 142 patients showed that oral administration of
dienogest for 4 months following conservative surgery for
endometriosis is as effective as the GnRH triptorelin depot
taken for the same period of time (Cosson et al., 2002). The
degree of pain symptoms reported was similar in the two
groups, as was the proportion of satis®ed subjects at the end of
treatment (86% in the dienogest arm versus 80% in the
triptorelin arm). Spotting was more frequent in the former
group (62 versus 25%) and vasomotor symptomatology more
frequent in the latter (10 versus 61%).
When dysmenorrhoea is the main symptom of a patient
undergoing surgical treatment for endometriosis, the insertion
of a slow-releasing levonorgestrel IUD at the end of the
procedure may substantially reduce the frequency and severity
of post-operative pain. We conducted a randomized study on
40 women with symptomatic endometriosis and scheduled for
operative laparoscopy (Vercellini et al., 2003a). Recurrent
moderate or severe dysmenorrhoea was observed within a year
of surgery in 2/20 (10%) women in the laparoscopy plus
medicated IUD group and in 9/20 (45%) of those allocated to
laparoscopy only. Hence, a medicated IUD needs to be inserted
intraoperatively in three patients in order to avoid recurrence of
dysmenorrhoea in one of them. One year after randomization,
75% of subjects allocated to the medicated IUD versus 50% of
those allocated to surgery only were satis®ed with the treatment
received.
Conclusions
Progestogens are effective in controlling pain symptoms in
approximately three out of four women with endometriosis.
Their effect does not seem to be inferior to that obtained with other
drugs habitually used in treating the disease. Medical treatment
plays a role in the overall therapeutic strategy only if it can be
administered over a prolonged period of time. Given their good
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tolerability, minor metabolic effects and low cost, progestogens
must therefore be considered the drugs of choice.
The effectiveness of progestogens is probably partly due to their
proven anti-in¯ammatory effect. Most pelvic lesions associated
with endometriosis are secondary to the strong in¯ammatory state
caused by the metabolic activity of ectopic endometrium and to the
resulting immune response. Furthermore, patients with endome-
triosis experience heavier menstruations than women without the
disease (Vercellini et al., 1997b). The reduction of menstrual ¯ow
observed with the use of OC or the levonorgestrel IUD can limit
pelvic contamination caused by transtubal re¯ux.
Progestogens are currently the only safe and inexpensive
alternative to surgery. However, their contraceptive effectiveness
limits their use to women who do not wish to have children in the
short term.
The role of laparoscopy in the medical treatment of endome-
triosis needs to be radically reconsidered. In fact, direct observa-
tion of the pelvis is not essential before starting therapy because
non-surgical diagnosis has proven suf®ciently reliable (Eskenazi
et al., 2001). The guidelines provided by the American College of
Obstetricians and Gynecologists (1999) as well as by the Royal
College of Obstetricians and Gynaecologists (2000) suggest that,
in the absence of adnexal masses, the administration of estrogen±
progestogen combinations can be undertaken without the need for
preliminary laparoscopy. Finally, experience shows that a repeat
laparoscopy is not important from either a clinical or an
experimental standpoint because this only monitors what is
inevitable: we do not need laparoscopy to know that endometriosis
implants have survived therapy. Endometriosis is not a cancer and
the systematic use of endoscopic follow-up should be removed
from clinical practice.
Future perspectives
Experimentation of products with greater tolerability should be
just one of the future objectives of clinical research on
progestogens in the treatment of endometriosis. Given the need
for long-term treatments, the minimum effective dosage needs to
be identi®ed in order to reduce the metabolic impact. Furthermore,
we will need to consider alternative administration modalities,
such as intravaginal (which should allow much higher pelvic
concentrations of the drug as opposed to serum concentrations)
and subcutaneous (which avoids the hepatic ®rst pass). The role
of adding estrogen in limiting erratic bleeding should be de®ned.
The medical treatment of rectovaginal lesions, which have always
been mistakenly considered the exclusive domain of the surgeon,
should be studied. Finally, we should not forget the option the
doctor has, under the current legislation, of prescribing galenical
preparations to be dispensed by the pharmacist. This makes it
possible to use progestogens that are no longer covered by
international patents and to administer them in the most appro-
priate dosage, thus avoiding the limits imposed by pharmaceutical
industries.
Progestogens applied to endometriosis, after an honoured career
in the past, now seem to have an even brighter future ahead, with
great bene®ts for the multitude of patients who suffer from this
chronic and sometimes disabling disease.
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